ReviewSub-cellular biochemistry2021
Fibrinogen and Fibrin.
Review in Sub-cellular biochemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 91 citations in OpenAlex.
- Review
- Insights into fibrinogen mechanics under cyclic high-strain loading.Biophysical journal · 2026Article
- Multifunctional Hydrogel-Based Scaffolds: Integrating Conductive Nanomaterials for Smart Wound Healing Applications.Gels (Basel, Switzerland) · 2026Review
- Acquired dysfibrinogenemia with discordant fibrinogen assays preceding the diagnosis of λ light-chain multiple myeloma: a case report.Thrombosis journal · 2026Article
- Gut metabolite TMAO and its structural analogs bind to fibrinogen thereby enhancing clot formation: a rationale for atherosclerosis risk.Scientific reports · 2026Article
- Fibrin as a Versatile Fibrous Biopolymer.Sub-cellular biochemistry · 2026Review
- Bioengineered Tricomposite Hydrogel Enhances Chondrogenic Phenotype and Hyaline Matrix Formation in Human Chondrocytes.Gels (Basel, Switzerland) · 2025Article
- Growth phase influences virulence inmSphere · 2025Article
- Epidemiology, fibrinogen, clot properties, and cardiovascular disease risk-an African perspective.Research and practice in thrombosis and haemostasis · 2025Article
- Antioxidant evolution of fibrinogen: a crucial role of methionines.Biophysical reviews · 2025Review
- Isolation and identification of bacteria from blood within 12 h using standard laboratory equipment.Scientific reports · 2025Article
- Reactive Nitrogen Species and Fibrinogen: Exploring the Effects of Nitration on Blood Clots.Antioxidants (Basel, Switzerland) · 2025Review
- A heterozygous nonsense mutation in the FGB gene (c.1299G > A) causes congenital fibrinogen disorder across four consecutive generations.Thrombosis journal · 2025Article
- Homocysteinylation of Fibrinogen: A Post-Translational Link to Thrombosis.International journal of molecular sciences · 2025Review
- Real-time imaging of blood coagulation and angiogenesis during development in a zebrafish model of type I antithrombin deficiency.Scientific reports · 2025Article
- In Vitro Evaluation of a Semi-Autologous Fibrin Sealant for Surgical Applications.Macromolecular bioscience · 2025Article
- Fibrinogen Oxidation and Thrombosis: Shaping Structure and Function.Antioxidants (Basel, Switzerland) · 2025Review
- The Proteome Content of Blood Clots Observed Under Different Conditions: Successful Role in Predicting Clot Amyloid(ogenicity).Molecules (Basel, Switzerland) · 2025Review
- Association between factor I fibrinogen (rs6050) and factor XI plasma thromboplastin (rs4253417) genetic polymorphisms and recurrent spontaneous miscarriage in Saudi women.Saudi medical journal · 2025Article
- Combined impact of prognostic nutritional index, fibrinogen-to-albumin ratio, and neutrophil-to-lymphocyte ratio on surgical outcomes and prognosis in hepatocellular carcinoma.American journal of cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrinogen is a large glycoprotein, synthesized primarily in the liver. With a normal plasma concentration of 1.5-3.5 g/L, fibrinogen is the most abundant blood coagulation factor. The final stage of blood clot formation is the conversion of soluble fibrinogen to insoluble fibrin, the polymeric scaffold for blood clots that stop bleeding (a protective reaction called hemostasis) or obstruct blood vessels (pathological thrombosis). Fibrin is a viscoelastic polymer and the structural and mechanical properties of the fibrin scaffold determine its effectiveness in hemostasis and the development and outcome of thrombotic complications. Fibrin polymerization comprises a number of consecutive reactions, each affecting the ultimate 3D porous network structure. The physical properties of fibrin clots are determined by structural features at the individual fibrin molecule, fibrin fiber, network, and whole clot levels and are among the most important functional characteristics, enabling the blood clot to withstand arterial blood flow, platelet-driven clot contraction, and other dynamic forces. This chapter describes the molecular structure of fibrinogen, the conversion of fibrinogen to fibrin, the mechanical properties of fibrin as well as its structural origins and lastly provides evidence for the role of altered fibrin clot properties in both thrombosis and bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.